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Abstract
The basal-like breast cancer, a new category of breast cancer associated with poor prognosis and
possibly unique chemosensitivity, is a current topic in the breast cancer field. Evidence from
multiple sources strongly indicate that impairment of BRCA1 pathways is responsible for this
phenotype, implying the importance of BRCA1 not only in familial breast cancers but also in
sporadic cancers. BRCA1 acts as a hub protein that coordinates a diverse range of cellular pathways
to maintain genomic stability. BRCA1 participates in multiple cellular supercomplexes to execute
its tasks and, in most of the complexes, BRCA1 exists as a RING heterodimer with BARD1 to
provide ubiquitin E3 ligase activity that is required for its tumor suppressor function. It was
revealed recently that the BRCA1 RING finger is capable of catalyzing multiple types of
ubiquitination depending upon the interacting E2, the ubiquitin carrier protein. BRCA1 may
catalyze distinct ubiquitination on different substrates as the situation demands. On the other hand,
in response to DNA double-strand breaks where BRCA1 plays its major role for homologous
recombination repair, recent evidence showed that ubiquitination is a critical step to recruit
BRCA1 to the damaged site through UIM (ubiquitin interacting motif) containing protein RAP80.
Thus, ubiquitin and BRCA1 likely affect each other in many ways to perform cellular functions.
Elucidation of this mechanism in relation to cell survival is now much anticipated because it could
be a key to predict chemosensitivity of basal-like breast cancer.
Introduction
The breast and ovarian cancer susceptibility gene BRCA1
is implicated not only in familial breast cancers but also
in sporadic breast cancers. Recently, the role of BRCA1 in
sporadic cancers became more apparent. Gene expression
profiling studies by high-throughput microarray analyses
have succeeded in categorizing breast cancer into several
subsets that are associated with distinct clinical outcomes,
including luminal A, luminal B, normal breast-like, HER2
overexpressing, and basal-like [1,2]. Approximately 15%
of sporadic breast cancers are categorized into the basal-
like subtype that expresses basal/myoepithelial cell mark-
ers, but does not express estrogen receptor (ER), progester-
one receptor (PR), or HER2 [1-3], and is associated with
poor prognosis. Impairment of BRCA1 pathways is likely
responsible for this subtype. For example, a majority of
hereditary breast cancers with BRCA1 mutations display a
basal-like phenotype [2,4-7], BRCA1 dysfunction in spo-
radic basal-like cancers has been reported [8-10], and con-
ditional deletion of BRCA1 and p53 in the mammary
gland of mice results in a phenotype reminiscent of
human basal-like breast cancer [11,12]. Because BRCA1's
function is implicated in the chemosensitivity of cells to
DNA damage-inducing reagents [13,14], elucidating the
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mechanisms of the BRCA1 pathways is now a critical issue
directly linked to the clinical breast cancer field.
When considering BRCA1's functions it should be
remembered that it is an enzyme, a ubiquitin E3 ligase
[15-17]. In addition, it was reported recently that polyu-
biquitin chains recruit BRCA1 to damaged DNA sites [18-
21], suggesting that ubiquitination plays key roles both
upstream and downstream of the BRCA1 pathways. How-
ever, the role of BRCA1's E3 activity in executing its cellu-
lar functions is still unclear. This review summarizes
BRCA1's function in the context of its relationship to
ubiquitin and discusses the possible roles of how the
activity is involved in its biological functions.
BRCA1 in multiple cellular supercomplexes
BRCA1 acts as a hub protein that coordinates a diverse
range of cellular pathways including DNA repair, cell cycle
control, transcriptional regulation, apoptosis, and centro-
some duplication to maintain genomic stability. BRCA1
participates in several different cellular supercomplexes to
coordinate these functions, and each complex contains
only a small fraction of the total cellular BRCA1 [22]. For
example BRCA2 interacts with only 5% or less of the total
BRCA1 [23]. Representative complexes include RNA
polymerase II holoenzyme complex (Pol II) [24], Mre11-
Rad50-Nbs1 (MRN) complex [25], BRCA2-Rad51 com-
plex [23,26], BACH1 (also called BRIP1 or FANCJ)-
TopBP1 complex [22,27], SWI/SNF chromatin remode-
ling complex [28], and a complex with γ-tubulin in the
centrosome [29]. Representative BRCA1 supercomplexes
that respond to DNA damage are shown in Figure 1.
BRCA1 interacts with many transcriptional cofactors and
regulates transcription. For example, BRCA1 stimulates
p53-dependent transcription of p21cip1/WAF1  [30-32].
BRCA1 that interacts with Pol II may act as a transcrip-
tional coactivator of some specific genes. Alternatively,
BRCA1 in the elongating Pol II complexes may also act as
a sensor for DNA damage [33,34]. In this model, BRCA1
dissociates from Pol II after certain types of DNA damage,
including those caused by the topoisomerase inhibitors
[33] or UV irradiation (our unpublished data) (Fig 1a).
On the other hand, BRCA1 associates with several differ-
ent protein supercomplexes in response to DNA double-
strand breaks (DSB) such as that introduced by ionizing
radiation (IR) or replication stress [22]. BRCA1 comprises
a complex with BRCA2 and Rad51 that mediates HR of
the DSBs (Fig 2d) [35-39]. BRCA1 also interacts with
MRN after DNA damage in a manner dependent on
checkpoint kinases ATM or Chk2 (Fig 2c) [22,25,40].
MRN mediates the G2/M checkpoint signal and plays
roles in DSB by holding two DNA ends close to each
other. This process is important for non-homologous
end-joining function and also precedes BRCA2-Rad51
mediated HR [14]. BRCA1 that interacts with MRN binds
to CtIP through the C-terminal BRCT domain [22]. The
BRCT domain of BRCA1 also interacts with phosphor-
ylated BACH1, ABRA1, and ATRIP [18,22,41-43]. BRCA1-
BACH1 interacts with TopBP1 in an ATM-dependent
manner after DNA damage and causes TopBP1 dissocia-
tion from the replication point, resulting in a failure to
recruit replication initiation factor Cdc45 [22] (Fig 2b).
This complex may be implicated in intra-S phase check-
point. ABRA1, also called coiled-coil containing protein
CCDC98, mediates the interaction between BRCA1 and
RAP80, which recruits BRCA1 to damaged DNA sites
through its ubiquitin-interacting motif (UIM), as
described below [18] (Fig 2e). Importantly, amongst its
many protein binding partners only BARD1 interacts sto-
ichiometrically with BRCA1 in cells and presumably exists
as a BRCA1-BARD1 RING heterodimer in most complexes
[22]. Because this dimer formation results in E3 ubiquitin
ligase activity [15,17,44], BRCA1 likely acts as an enzyme
in many cellular complexes and directs the ubiquitination
of distinct substrates within each complex.
BRCA1-BARD1 RING heterodimer E3 ligase
The ubiquitin system consists of three critical enzymes: a
ubiquitin-activating enzyme (E1), a ubiquitin-conjugat-
ing enzyme (E2), and a ubiquitin ligase (E3). The E3 cat-
alyzes the formation of polyubiquitin chains (or
sometimes monoubiquitin), utilizing ubiquitins that
have been activated by the E1 and E2 enzymes, and trans-
fers them onto specific substrate(s) via isopeptide bonds
[45,46].
The BRCA1 gene encodes a protein of 1,863 amino acids
with a molecular weight of 220 kDa [47]. The protein con-
tains an N-terminal RING finger domain, a common E2
binding motif found in E3 ligases, and tandem BRCT
domains in its C-terminal region. The N-terminal RING
finger domain of BRCA1 interacts with another conforma-
tionally similar RING finger protein, BARD1, that con-
tains an N-terminal RING domain and C-terminal
tandem BRCT domains [48] to constitute a RING het-
erodimer E3 ligase [15,17,44]. The BARD1 interaction is
required to stabilize the proper conformation of the
BRCA1 RING domain for E3 activity [44]. The RING fin-
ger of BRCA1 interacts with E2 UbcH5 whereas the role of
the BARD1 RING domain is currently unknown. The
BRCT repeats constitute a phosphopeptide recognition
domain that binds peptides containing a phospho-SXXF
motif [41,42]. Because BRCA1 BRCT domains form mutu-
ally exclusive complexes with CtIP, BACH1, and ABRA1 in
a phosphorylation-dependent manner, it has been pro-
posed that these proteins may serve as adaptor proteins to
target the BRCA1-BARD1 E3 ligase to specific substrates
[18,49]. In this regard, these complexes resemble the SCF
(Skp1, CUL1, F-box) complex where the N-terminus ofCell Division 2008, 3:1 http://www.celldiv.com/content/3/1/1
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BRCA1 supercomplex formation in response to DNA damage Figure 1
BRCA1 supercomplex formation in response to DNA damage. BRCA1 acts in many cellular supercomplexes and exe-
cutes distinct roles. BARD1 stoichiometrically interacts with BRCA1 and exists as a RING heterodimer in all the complexes 
shown, indicating the importance of E3 ligase activity in each complex. (a) BRCA1-BARD1 in the Pol II-holoenzyme may act as 
a transcriptional co-activator. In addition, BRCA1 that interacts with hyperphosphorylated Pol II acts as a sensor for DNA 
damage. After some types of DNA damage, BRCA1 dissociates with Pol II. BRCA1-BARD1 may polyubiquitinate subunits of 
this complex at this time, including the hyperphosphorylated largest subunit (RPB1) and the common small subunit (RPB8). (b) 
BRCA1 that interacts with BACH1/BRIP1/FANCJ at its C-terminus locates the replication point with BARD1. This complex 
interacts with TopBP1 in an ATM dependent manner after DNA damage and causes TopBP1 dissociation from the replication 
point. This results in the failure to recruit the replication initiation factor Cdc45, likely engaging the intra S-phase checkpoint. 
(c) Mre11-Rad50-Nbs1 also forms a complex with BRCA1-BARD1 at sites of DNA damage. This BRCA1 complex interacts 
with CtIP via the BRCA1 C-terminus. Complex formation depends on ATM- and Chk2-mediated phosphorylation. This com-
plex signals the G2/M checkpoint and bridges the two DNA ends of the DSB, an intermediate of both non-homologous end 
joining (NHEJ) and homologous recombination (HR). (d) BRCA1 constitutes S-phase nuclear foci with BARD1, Rad51 and 
BRCA2. After DNA damage, these once disperse foci again localize to damaged DNA sites. BRCA1 is necessary for recruiting 
these proteins. This complex is important for homologous recombination repair of DSB. (e) BRCA1-BARD1 is targeted to 
polyubiquitin chains at DNA damaged sites through BRCT domain-interacting phosphorylated ABRA1 that interacts with UIM 
containing protein RAP80.
ATRIP
Transcription, DNA damage sensor ?
CstF50 BARD1
BRCA1
P P P P Pol II
BARD1
BRCA1
ATM
Chk2 ATR
DNA-PK
DNA damage
P P P P Pol II
(a)
(b)
(c)
(d)
Chk1
Rad50
Mre11
Nbs1
BARD1
BRCA1
Rad50
Mre11
Nbs1
Non-
homologous 
end-joining
G2/M 
checkpoint 
signal
CtIP
BARD1
BRCA1
CtIP
P
MSH2
MSH6
Intra-S 
checkpoint 
signal TopBP1
TopBP1
BARD1
BRCA1
BACH1
MLH1
BARD1
BRCA1
BACH1
Replication inhibition
DNA replication point
P
(e)
BARD1
BRCA1 BARD1
BRCA1
ABRA1
RAP80 ABRA1
RAP80
uu
uu K6 or K63-link
P
BRCC36(DUB)
P
supercomplex
phosphorylation
BRCA2/FANCD1
BARD1
BRCA1
Rad51
BRCA2/FANCD1
BARD1
BRCA1
Rad51
Homologous 
recombination
Once 
dispersed 
S-phase dot
uu
uu
Polyubiquitin cahinsCell Division 2008, 3:1 http://www.celldiv.com/content/3/1/1
Page 4 of 10
(page number not for citation purposes)
Models for ubiquitin accumulation at DSB Figure 2
Models for ubiquitin accumulation at DSB. Upon DSBs, γH2AX could be monoubiquitinated (a) so that RNF8-Ubc13-
Mms2 can attach additional Lys63-linked polyubiquitin chains on the ubiquitin (b). The E2 and E3 for monoubiquitination are 
unknown. BRCA1-BARD1 is then targeted to the polyubiquitin chains through RAP80-ABRA1 in a manner dependent on 
ABRA1 phosphorylation. BRCA1-BARD1 interacts with UbcH5c and mediates further polyubiquitin chains, including Lys6-
linked chains (c). The BRCA1-BARD1-induced polyubiquitin chains further recruit additional BRCA1-BARD1 complexes to 
damaged sites, resulting in focal accumulation of polyubiquitin chains (d). The polyubiquitin chain assembly is likely required for 
BRCA2-Rad51 recruitment to damaged sites, allowing execution of homologous recombination repair. Recent studies suggest 
that the BRCA1-BARD1 heterodimer could also catalyze substrate monoubiquitination with substrate-specific E2s, such as 
UbcH6, Ube2e2, UbcM2, and Ube2w, as well as additional Lys63-linked polyubiquitin chains with Ubc13-Mms2. The sub-
strate(s) and the timing of this action remain to be determined.
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CUL1 interacts via Skp1 with F-box adaptor proteins that
recruit specific substrates in a phosphorylation dependent
manner while the C-terminus of CUL1 interacts with the
RING subunit ROC1/Rbx1 [50-53]. Identification of sub-
strates ubiquitinated by BRCA1-BARD1 in such a structur-
ally similar manner is of great interest. On the other hand,
the other regions of BRCA1, including that encoded by the
largest coding exon 11, as well as N-terminal regions adja-
cent to the RING domain, also bind to many critical cellu-
lar proteins, some of which have been reported to be
ubiquitinated by BRCA1-BARD1.
Substrate recognition sites of BRCA1
Putative substrates of BRCA1-BARD1 identified at present
are histones, γ-tubulin, ERα, nucleophosmin/B23
(NPM1), the largest subunit of RNA polymerase II
(RPB1), CtIP, the common subunit of RNA polymerases
(RPB8), progesterone receptor-A (PR-A), and the general
transcription factor TFIIE [49,54-62].
The substrate recognition sites for the majority of these
substrates are distributed throughout the N-terminus half
of BRCA1. Ubiquitination of histone H2A and H2AX
requires N-terminal residues 1–639 of BRCA1 [54]. The
hyperphosphorylated forms of full-length RPB1
(RNAPIIO) can be polyubiquitinated by N-terminal resi-
dues 1–304 of BRCA1 in vitro[55]. However, it has also
been reported that the C-terminus of BRCA1 is required
for efficient RPB1 ubiquitination in vivo despite the result
that N-terminal residues 1–500 of BRCA1 are sufficient to
ubiquitinate the C-terminal domain (CTD) of RPB1 in
vitro [56]. NPM1 and RPB8 were also ubiquitinated by the
N-terminal constructs of BRCA1 in vivo and in vitro
[57,58]. Although NPM1 was only poorly ubiquitinated
with recombinant BRCA1 residues 1–304 and BARD1 res-
idues 14–189 [57], it was effectively polyubiquitinated
with residues 1–772 of BRCA1 and full-length BARD1 in
vitro (unpublished data), suggesting that the BRCT
domains of BRCA1 are dispensable for this substrate. In
some cases substrate recognition appears to occur via a
combination of BRCA1 and BARD1 sequences. For exam-
ple, ubiquitination of ERα requires N-terminal BRCA1
residues 1–241 in combination with N-terminal BARD1
residues 1–170 [59]. In contrast substrates recognized by
the C-terminus of BRCA1 include γ-tubulin and CtIP. Full-
length BRCA1, including C-terminal residues 1852–1863,
was necessary for γ-tubulin monoubiquitination,
although the domains required for γ-tubulin binding
reside in the amino-terminal 803 amino acids of BRCA1
[60]. CtIP interacts with BRCT and is polyubiquitinated
by BRCA1-BARD1 in a phosphorylation dependent man-
ner. In this case, the BRCT domains play the role of a sub-
strate recruitment adaptor, the function similar to the F-
box proteins within the SCF complex [49]. From this per-
spective, it could be interesting to test whether the BRCT
binding proteins BACH1 and ABRA1 are also ubiquiti-
nated by BRCA1.
Types of ubiquitination and signals
Biological consequences for the ubiquitination of the
above substrates are not yet completely understood. One
of the reasons for this difficulty is that the signal mediated
by BRCA1-induced ubiquitination has not been deter-
mined. Depending upon the type of ubiquitin chain,
ubiquitin modifications signal a variety of processes [63-
65]. The most common polyubiquitin chains are linked
through Lys48 of ubiquitin and serve as a signal for prote-
olysis by the proteasome [66]. However, BRCA1-BARD1
catalyzes unconventional polyubiquitin chains that
include Lys6-linked chains [67-69]. Putative degradation
substrates reported at present are RNAPIIO and PR-A
[55,61]. Because double knock-down of BRCA1 and
BARD1 restored the expression level of the RNAPIIO that
had been repressed by UV irradiation, it was proposed
that BRCA1-BARD1 could initiate the degradation of
stalled RNAPIIO [55]. However, the BRCA1/BARD1 dou-
ble knock-down did not detectably affect RPB1 ubiquiti-
nation after UV irradiation. Therefore, the restored
expression level of RNAPIIO by BRCA1/BARD1 double
knock-down could be due to an indirect effect. PR-A is sta-
bilized in the absence of BRCA1 in knockout mice as well
as in siRNA knock-down cells [61]. Importantly, anti-pro-
gesterone treatment dramatically inhibits breast carcino-
genesis in mice defective for BRCA1 and p53, indicating
that downregulation of PR-A by BRCA1 is critical to pre-
vent breast cancer. In this process, PR-A has been shown
to be ubiquitinated by BRCA1 overexpression in vivo.
However, the BRCA1/BARD1 complex did not ubiquiti-
nate PR-A in vitro [61]. Therefore, to date there is no direct
evidence supporting the notion that BRCA1-mediated
ubiquitination signals degradation.
On the other hand, numerous substrates have been
shown not to be degraded by BRCA1-catalyzed polyubiq-
uitination: NPM1, CtIP, RPB8, TFIIE and BRCA1 itself
[49,57,58,62,67]. BRCA1 autoubiquitinates when bound
to BARD1, and the ubiquitination stabilizes BRCA1 and
enhances its E3 activity, suggesting a positive feedback
effect for activity [15,67,70]. Although detailed biochem-
ical mechanisms regarding the ubiquitination signal
remain to be elucidated, the ubiquitination of these sub-
strates results in some biological effects. Ubiquitinated
CtIP associates with chromatin after γ-radiation, and this
ubiquitination could be important for CtIP focus forma-
tion at the DNA damaged site. This is because only wild-
type BRCA1, but not the I26A E3 ligase mutant of BRCA1,
restored DNA damage-induced CtIP focus formation in
BRCA1-deficient HCC1937 cells [49]. Consistent with a
role for the BRCA1-CtIP complex in G2/M checkpoint
control, BRCA1-I26A did not restore the G2/M check-Cell Division 2008, 3:1 http://www.celldiv.com/content/3/1/1
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point of HCC1937 cells while wild type BRCA1 did. In
contrast to the chromatin association of ubiquitinated
CtIP, BRCA1 ubiquitination of TFIIE, a subunit of the
basal transcription factor, causes its dissociation from the
transcription pre-initiation complex at the promoter and
blocks the initiation of mRNA synthesis [62]. In addition
to the basal transcription factor, the common subunit of
all three RNA polymerases, RPB8, is also polyubiquiti-
nated by BRCA1 [58]. RPB8 was polyubiquitinated imme-
diately after ultra-violet (UV) irradiation, and this
ubiquitination was inhibited by BRCA1 knock-down via
RNA interference. BRCA1 knock-down also resulted in
decreased RPB8 protein in the soluble cellular fraction,
suggesting that BRCA1 ubiquitination of RPB8 may cause
dissociation of RPB8 from chromatin-associated com-
plexes in a fashion similar to TFIIE dissociation from the
pre-initiation complex. The ubiquitination of RPB8 is
likely not important for normal transcriptional processes
because a ubiquitin-resistant form of RPB8 preserves its
polymerase activity and HeLa cells stably expressing this
mutant grow normally. However, this cell line exhibited
UV hypersensitivity [58], suggesting that ubiquitination
of RPB8 is important for BRCA1-dependent cell survival
after DNA damage, which could be caused by inhibition
of synthesis of mRNA or other RNAs. The biological sig-
nificance of NPM1 ubiquitination by BRCA1 is currently
unknown. Because NPM1 has multiple cellular functions
implicated in BRCA1's function, such as histone chaper-
one activity, licensing of centrosome duplication, regula-
tion of the ARF-MDM2-p53 pathway and inhibition of
apoptosis, it will be important to investigate the role of
BRCA1 ubiquitination of NPM1 in these biological func-
tions.
BRCA1 also catalyzes the monoubiquitination of some
substrates. Core histones H2A, H2B, H3, and H4 are all
monoubiquitinated in vitro [54,70]. In addition, phos-
phorylated DNA damage responsive histone variant
H2AX (γH2AX) is also monoubiquitinated in vitro
[54,70]. Although the biological significance of this
monoubiquitination is poorly understood, it could con-
tribute to chromatin remodeling in BRCA1-dependent
DNA repair pathways. γ-tubulin is also monoubiquiti-
nated by BRCA1 in vitro and mutation of the monoubiq-
uitination site on γ-tubulin results in centrosome
hyperamplification, suggesting that BRCA1 regulates cen-
trosome number and proper nuclear segregation through
γ-tubulin monoubiquitination [60]. Another substrate
reported to be monoubiquitinated is ERα [59]. The lig-
and-binding domain of ERα is monoubiquitinated by
BRCA1-BARD1 in vitro.
E2 specificity of the BRCA1 RING
As the above discussion makes clear, ubiquitination by
BRCA1 is a diverse process, likely with different fates for
different substrates. One question that arises is how
BRCA1 catalyzes its different ubiquitination products. A
clue to this conundrum has recently been reported, show-
ing that specific E2-BRCA1 RING interactions determine
the type of ubiquitination [71]. Surprisingly, the RING
finger domain of BRCA1 is capable of interacting with
UbcH6, UbcH7, Ube2e2, UbcM2, Ube2w, Ubc13, and
Ube2k in addition to UbcH5, the E2 previously known to
interact with BRCA1, through conserved residues located
in Helix 1 and Loop L2 of each E2. Mutation of key resi-
dues in these regions, such as A96D in Loop L2 of
UbcH5c, eliminates the interaction. BRCA1-BARD1 in
combination with UbcH6, Ube2e2, UbcM2, or Ube2w
resulted in monoubiquitination of BRCA1 while in com-
bination with UbcH5c resulted in polyubiquitination. In
contrast, incubation of BRCA1-BARD1 with UbcH7,
Ubc13-Mms2 or Ube2k did not catalyze ubiquitin transfer
from the E2s, even though they bind to the BRCA1 RING.
Unexpectedly, incubation of BRCA1-BARD1 with Ubc13/
Mms2 or Ube2k in the presence of Ube2w resulted in
polyubiquitination of BRCA1 that was perturbed by K63R
or K48R mutation of ubiquitin, respectively. The nature
and location of the non-covalent interaction between the
acceptor monoubiquitinated ubiquitin molecule on
BRCA1 and either Mms2 or the C-terminus of Ubek2 play
critical roles for polyubiquitination assembly and the
determination of the specific chain linkages. Based on the
above observations, Christensen et al. [71] classified
Ubc13-Mms2 and Ube2k as ubiquitin-specific E2s for
BRCA1 and classified UbcH6, Ube2e2, UbcM2 and
Ube2w as substrate-specific E2s for BRCA1. The ubiqui-
tin-specific E2s conjugate ubiquitin to another ubiquitin,
while the substrate-specific E2s transfer ubiquitin directly
to the BRCA1 substrate, but not to ubiquitin itself.
UbcH5c is unique in its ability to both transfer the first
ubiquitin to BRCA1 and extend the chain. The discovery
of this E2-BRCA1 RING specificity may contribute to
progress in many aspects of research into BRCA1 function.
For example, BRCA1's ability to catalyze Lys48-linked
chains may explain the BRCA1-mediated ubiquitination
of and proteasome-dependent degradation of RNAPIIO
and PR-A, as described above [55,61]. It is also possible
that the previously known monoubiquitinated substrates,
such as histones and γ-tubulin, could be substrates for
polyubiquitination with additional E2s. For instance,
γH2AX is only monoubiquitinated in vitro in previously
reported reactions using a single E2 [54,70] although it
can be polyubiquitinated in vivo in response to γ-radia-
tion in a Ubc13-dependent manner [72]. In addition,
many candidate substrates may have been discarded in
previous in vitro studies that used only UbcH5 as the E2.
Assay of such candidate substrates with BRCA1-BARD1
and the panel of E2s with which it works may reveal over-
looked targets.Cell Division 2008, 3:1 http://www.celldiv.com/content/3/1/1
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Polyubquitin chain recruits BRCA1 to damaged DNA sites
One of the most important functions of BRCA1 is its role
in DNA double-strand breaks (DSBs). BRCA1 and BARD1
are required to recruit Rad51 and BRCA2, the central play-
ers in HR at damaged DNA sites [22,35-39]. The E3 ligase
activity of BRCA1 could be critical in this function. How-
ever, the collaboration between BRCA1 and ubiquitin
goes beyond this relationship. It was reported recently
that BRCA1 is recruited to the DSBs by polyubiquitin
chains through RAP80, a ubiquitin interacting motif
(UIM) containing protein that had previously been char-
acterized as an ERα-interacting nuclear protein [18-
21,73](Figure 2). RAP80 constitutes a protein complex
with ABRA1 that interacts with BRCT domain of BRCA1 in
a phosphorylation dependent manner [18]. Upon DSBs,
RAP80-ABRA1 targets the BRCA1-BARD1 complex and
the deubiquitinating (DUB) enzyme BRCC36 to Lys6-
and Lys63-linked polyubiquitin chains at DSBs [18,19].
These polyubiquitin chain assemblies were MDC1- and
γH2AX-dependent [19]. Strikingly, the substrates of the
polyubiquitin chains, as well as the E3 that catalyzed
them, were recently determined to be H2AX and RNF8,
respectively [74-77]. RNF8 contains an N-terminal fork-
head-associated (FHA) domain and a C-terminal RING
domain. While RNF8 is recruited to MDC1 through a
phosphorylation-dependent interaction between the FHA
domain and motifs in MDC1 that are phosphorylated by
ATM, the RING domain polyubiquitinates H2AX or H2A.
Knockdown of RNF8 by siRNA impaired IR-induced poly-
ubiquitination of H2AX [75] and inhibited BRCA1's focus
formation at DSB sites [74-77], indicating that RNF8 acts
upstream of BRCA1. Because knockdown of Ubc13, an E2
known to form K63-linked polyubiquitin chains, also
inhibited BRCA1 and RAP80 focus formation [74-77] and
because RNF8 interacted with Ubc13 [78], it is likely that
the E2 cooperating with RNF8 in the pathway is Ubc13.
However, in vitro H2A or H2AX polyubiquitination medi-
ated by RNF8 and Ubc13 remains to be shown. Only
polyubiquitination of histones mediated by RNF8 and
UbcH5c has been demonstrated at present [74].
It was also previously reported from another group that
Ubc13-dependent polyubiquitination is required for HR
[72]. A complex comprised of the E2 Ubc13-Mms2 and E3
Rad5 complex catalyzes Lys63-linked polyubiquitin
chains on the Rad6/Rad18-induced monoubiquitinated
PCNA that is implicated in post-replication repair in bud-
ding yeast [79-81]. In vertebrates, however, it was shown
using Ubc13-deficient DT40 cells that Ubc13 is required
to repair a wide range of DNA-damage including that
caused by IR, UV, H2O2, and DNA crosslinking or DSB-
causing chemical reagents [72]. Ubc13-deficient DT40
cells exhibited prolonged γH2AX foci formation after IR
accompanied by loss of Rad51 and conjugated-ubiquitin
containing foci formation (detected by FK2 antibody),
suggesting that the Ubc13-mediated ubiquitination is
required for Rad51-mediated HR. Importantly, siRNA
knock-down of Ubc13 in HeLa cells eliminated E3 ligase
activity of BRCA1 immunocomplexes precipitated from
IR treated cells when incubated with ubiquitin, E1 and
ATP, but not with E2. Because the immunocomplex's loss
of E3 ligase activity was accompanied by dissociation of
IR-induced interaction of UbcH5c with the complex, it
was speculated that Ubc13 activates BRCA1's E3 activity
by enhancing the BRCA1-UbcH5c interaction [72]. There-
fore, one possible model is that upon DSBs, RNF8-Ubc13-
Mms2 catalyzes Lys63-linked polyubiquitin chains on
γH2AX (Figure 2). RAP80-ABRA1 targets BRCA1-BARD1
to the polyubiquitin chains where UbcH5c interacts with
BRCA1 and catalyzes Lys6-linked polyubiquitin chains.
The Lys6-linked polyubiquitination might be recognized
again by RAP80 to cause auto-amplification of the ubiqui-
tination signal at the DNA damaged focus. Polyubiquitin
chain assembly is required for further processes of HR,
including RPA binding to single strands and recruitment
of Rad51 [72]. In this model, an E2 and an E3 that medi-
ate monoubiquitination of γH2AX prior to RNF8-Ubc13-
Mms2-mediated Lys63-linked polyubiquitination could
be required. An additional candidate E3 that interacts
with Ubc13 in the pathway includes the human homo-
logue of Rad5, SHPRH, that was recently identified to
interact with Rad6-Rad18 and Mms2-Ubc13 and to poly-
ubiquitinate PCNA [82]. However, PCNA likely is not the
Lys63-linked polyubiquitinated substrate of Ubc13-
dependent ubiquitination in DSBs. This is because Rad51
focus formation after IR was not perturbed in the DT40
cells in which Lys165 of PCNA (the Rad6-Rad18- and
Mms2-Ubc13-dependent ubiquitination site) was
replaced by arginine [72]. Other E3s that interact with
Ubc13 include CHFR and TRAF6 [83,84]. Furthermore,
now it is known that Ubc13 can interact directly with
BRCA1 RING and is capable of assembling Lys63-linked
polyubiquitin chains on monoubiquitinated substrate
[71]. How and when BRCA1-BARD1 cooperates with a
substrate-specific E2, such as UbcH6, Ube2e2, UbcM2, or
Ube2w, as well as a ubiquitin-specific E2, such as Ubc13/
Mms2 or Ube2k, would be an interesting matter to be
determined. In this regard, deficiencies in some of these
E2s may also affect HR after DSBs.
Conclusion
BRCA1-BARD1 likely acts as an E3 in many cellular com-
plexes and directs the ubiquitination of distinct substrates
within each complex. Its putative substrates identified at
present are histones, γ-tubulin, ERα, NPM1, RPB1, RPB8,
CtIP, PR-A, and TFIIE. Ubiquitination by BRCA1 is a
diverse process, likely with different fates for different sub-
strates. Incubation of BRCA1-BARD1 with ubiquitin-spe-
cific E2s, such as Ubc13/Mms2 or Ube2k, in the presence
of substrate-specific E2s, such as Ube2w, resulted in K63-Cell Division 2008, 3:1 http://www.celldiv.com/content/3/1/1
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linked or K48-linked polyubiquitin chains, respectively,
in addition to K6-linked polyubiquitin chains mediated
by UbcH5. These in vitro results remain to be fully vali-
dated. On the other hand, the ubiquitination-dependent
BRCA1 recruiting mechanism after DSB has been eluci-
dated, and γH2AX polyubiquitination, RNF8, Ubc13,
RAP80, and ABRA1 were involved in the system. Turnover
of polyubiquitinated structures by DUB activity, such as
by BRCC36 or BAP1, may further regulate this reaction.
Thus, many actors have appeared on the stage of BRCA1
E3 ligase activity after DSB and are awaiting the script of
BRCA1 substrate and their roles in the pathway.
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